Description
Axicabtagene ciloleucel as new standard of care for second-line treatment of DLBCL patients: from pivotal data to real-world evidence
Article: Axicabtagene ciloleucel as new standard of care for second-line treatment of DLBCL patients: from pivotal data to real-world evidence
€3.03
Reviews
There are no reviews yet.